Articles

Does Lilly have enough on Alzheimer’s drug?

After Eli Lilly and Co. found a “glimmer of hope” in its test of its experimental Alzheimer’s drug, doctors and stock analysts generally concluded the company needs to conduct another long clinical trial to prove the drug’s effect. But one stock analyst thinks Lilly already has what it needs to ask for approval for its drug.

Read More

Boneham supports hybrid health exchange for state

The Libertarian candidate for governor said he initially favored a state-run exchange to administer the federal health care law, but chose a joint venture with the federal government after meeting with the governor's staff.

Read More

$100M IU neuroscience center set to open

A $100 million neuroscience center Indiana University officials say will offer a "one stop shop" for patients recovering from head and spinal injuries, strokes and other medical conditions is days away from opening its doors in Indianapolis.

Read More

WellPoint CEO’s critics suggesting replacements

Another plea for the ouster of WellPoint CEO Angela Braly is spurring discussions among investors and analysts about a replacement. Top suggestions include James G. Carlson, the chief of Amerigroup Corp., and David B. Snow Jr., the former chief of Medco Health Solutions Inc.

Read More

Lilly’s Alzheimer’s drug trials show mixed results

Eli Lilly and Co.’s experimental Alzheimer’s drug failed to meet its primary goals in two separate clinical trials. However, when the results of both trials were combined, the drug appeared to have slowed the decline of cognition in some patients.

Read More

Rival’s strong results have WellPoint playing catch-up

UnitedHealth has been enjoying healthy profits, growing customer rolls and a rising stock price—things the Indianapolis insurer has been unable to match. That tough comparison lies behind some of the investor attacks on WellPoint CEO Angela Braly.

Read More

GOP govs: Not enough Medicaid ‘flexibility’

The Obama administration is giving states like Indiana a little flexibility in how to expand their Medicaid programs—but nothing like what state officials hoped for after the U.S. Supreme Court struck down part of the law in late June.

Read More